Highlights Immunome, Inc.

Equities

IMNM

US45257U1088

Real-time Estimate Cboe BZX Other stock markets 11:41:48 14/05/2024 pm IST			5-day change	1st Jan Change
14.82 ^USD	-5.06%		-3.13%	+38.79%

12:00am	Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI
12:00am	Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25/03	CI
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	07/02	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	06/02	CI
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	08/01	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	26/12	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	26/12	CI
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Immunome, Inc. completed the acquisition of MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others.	02/23/02	CI
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Immunome, Morphimmune Agree to Merge in All-Stock Deal	29/23/29	MT
Immunome, Inc. entered into an agreement to acquire MorphImmune, Inc.	29/23/29	CI
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Immunome, Inc. Enter into A Collaboration and Option Agreement with AbbVie Global Enterprises Ltd	06/23/06	CI
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Immunome Says 'Encouraged' by Preclinical Data in Cancer Trial	09/22/09	MT
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting	07/22/07	CI
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer	23/22/23	CI
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	05/22/05	CI
Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1	06/22/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunome, Inc.

Equities

IMNM

US45257U1088

Highlights

Filters